MAP2K1 and cardiofaciocutaneous syndrome: Indeed, a recent multinational cohort study of 138 individuals with CFC syndrome indicated that patients with a MEK1(Y130C) mutation exhibited a considerably higher prevalence and severity of neurologic symptoms, including treatment‐resistant severe epilepsy, than those with other MEK mutations [43].